Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease Endpoints News

Image for article Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease  Endpoints News
News Source : Endpoints News

News Summary

  • At $65 a share, Ver­tex will pay a sub­stan­tial pre­mi­um for Alpine, whose stock $ALPN closed Tues­day at $37
  • 57
  • Alpine Im­mune Sci­ences and its ex­per­i­men­tal drug povetaci­cept are being sold
Reshma Kewalramani is putting Vertexs $10 billionplus balance sheet to work.On Wednesday, the biotech announced it would pay $4.9 billion for Alpine Immune Sciences and its experim [+579 chars]

Must read Articles